Get the Stockscreener App
1.48
7.25%
0.10
After Hours:
1.44
-0.04
-2.70%
Autonomix Medical Inc stock is traded at $1.48, with a volume of 191.85K.
It is up +7.25% in the last 24 hours and down -20.43% over the past month.
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
See More
Previous Close:
$1.38
Open:
$1.37
24h Volume:
191.85K
Relative Volume:
0.99
Market Cap:
$4.52M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.92%
1M Performance:
-20.43%
6M Performance:
-62.53%
1Y Performance:
-95.89%
1-Day Range:
$1.37
$1.50
1-Week Range:
$1.30
$1.70
52-Week Range:
$1.30
$42.40
Autonomix Medical Inc Stock (AMIX) Company Profile
Name
Autonomix Medical Inc
Sector
Industry
Phone
832-277-7816
Address
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
Compare AMIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
1.48 | 4.52M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Autonomix Medical Inc Stock (AMIX) Latest News
Autonomix set to expand cancer pain treatment trial - Investing.com India
Autonomix granted approval to expand PoC human clinical trial - TipRanks
Autonomix (AMIX) Gains Approval for New Clinical Trial Phase in Uzbekistan | AMIX Stock News - GuruFocus
Autonomix set to expand cancer pain treatment trial By Investing.com - Investing.com Nigeria
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain - Yahoo
Autonomix Medical, Inc. (NASDAQ:AMIX) Sees Large Decrease in Short Interest - Defense World
Autonomix Medical, Inc. SEC 10-K Report - TradingView
Autonomix Medical (NASDAQ:AMIX) Stock Price Down 4.3% – What’s Next? - Defense World
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech - MSN
Autonomix picks up key nerve ablation catheter patent - MassDevice
Autonomix granted key U.S. patent for catheter-based platform technology - TipRanks
Autonomix (AMIX) Secures New Patent for Nerve Treatment Technolo - GuruFocus
Autonomix (AMIX) Secures New Patent for Nerve Treatment Technology | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology - The Manila Times
Breakthrough Patent: How Autonomix Medical's New Nerve-Mapping Tech Could Transform Pain Treatment - Stock Titan
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event - GlobeNewswire
Exclusive Live Access: Autonomix CEO Reveals Game-Changing Neural Sensing Technology to Investors - Stock Titan
Autonomix CEO outlines follow-on expansion study expected to begin in Q2 - TipRanks
Autonomix plans expansion phase for cancer pain trial - Investing.com
AMIX Expands Clinical Trials to Target Broader Cancer Pain Marke - GuruFocus
AMIX Expands Clinical Trials to Target Broader Cancer Pain Market | AMIX Stock News - GuruFocus
Autonomix plans expansion phase for cancer pain trial By Investing.com - Investing.com India
Autonomix Medical, Inc. Announces Follow-On Phase of Clinical Trial to Expand Treatment Options for Cancer Pain Management - Nasdaq
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines - GlobeNewswire
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market - Stock Titan
Ananda Pharma, Accsys Technologies, Autonomix Medical, BitwiseSmall Cap Week in Review - Research Tree
Autonomix Medical reports promising results in first-in-human trial for novel cancer pain therapy - Proactive financial news
Autonomix reports significant pain relief in cancer trial - Investing.com
Autonomix reports significant pain relief in cancer trial By Investing.com - Investing.com India
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain - GlobeNewswire
Breakthrough Cancer Pain Treatment Eliminates Opioid Use in 100% of Responding Patients, Trial Shows - Stock Titan
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic Cancer Pain Treatment | AMIX Stock News - GuruFocus
Autonomix advances pain treatment in cancer trials By Investing.com - Investing.com Australia
Autonomix advances pain treatment in cancer trials - Investing.com
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - The Manila Times
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Autonomix Medical, Inc. Reports Positive Outcomes in - GlobeNewswire
Revolutionary Cancer Pain Treatment Shows 100% Success Rate: Autonomix Medical's Breakthrough Trial Results - Stock Titan
Autonomix Medical Inc Stock (AMIX) Financials Data
There is no financial data for Autonomix Medical Inc (AMIX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.56%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):